XML 29 R77.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Collaborative and Other Relationships Collaborative and Other Relationships - Collaboration Agreement (Details) (USD $) In Millions, unless otherwise specified |  | 3 Months Ended | 1 Months Ended |
--- | --- | --- | --- | ---
Mar. 31, 2014 Eisai | Mar. 31, 2014 Sangamo BioSciences | Jan. 31, 2014 Isis Pharmaceuticals | Mar. 31, 2014 Research and development Eisai
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Total upfront and milestone payments | $ 100.0 | $ 20.0 |  |
Amount recorded to reflect fair value of options granted |  |  |  | 17.7
Research and development expense |  | 20.0 | 45.0 |
Additional milestone payment | $ 1,000.0 | $ 300.0 |  |

X
- Definition Additional milestone payment. + References No definition available. + Details
Name: | biib_AdditionalMilestonePayment
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Liability For Fair Value Of Options Granted Under Agreement + References No definition available. + Details
Name: | biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Total upfront and milestone payments made to collaborative partner. + References No definition available. + Details
Name: | biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration